Krystal Biotech, Inc.
KRYS
$312.57
-8.37%
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines for diseases with high unmet medical needs. The company leverages its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells, with its lead product VYJUVEK approved for dystrophic epidermolysis bullosa. As a pioneer in topical gene therapy, Krystal Biotech holds a unique competitive position as the first and only approved treatment for this rare skin disorder, with exclusive rights to develop and commercialize VYJUVEK internationally. The current investor narrative centers on the company's rapid revenue growth from VYJUVEK, expansion into new geographic markets (EU and Japan), and the potential of its pipeline to address additional indications, which has driven the stock to significant gains over the past year despite recent volatility.…
KRYS
Krystal Biotech, Inc.
$312.57
Related headlines
Investment Opinion: Should I buy KRYS Today?
Based on the strong financial performance, accelerating revenue growth, and analyst consensus, KRYS is rated a Buy. The company has demonstrated robust execution with Q1 2026 revenue up 31.95% YoY and a net margin of 48.07%, supporting a positive outlook. The average analyst target of $376.75 implies 10.4% upside, and the strong buy recommendation from 8 analysts reinforces the bullish stance.
Sign up to view all
KRYS 12-Month Price Forecast
The AI assessment is bullish on KRYS, driven by its strong revenue acceleration, exceptional margins, and attractive valuation on a PEG basis. The company's unique platform and first-mover advantage in topical gene therapy provide a competitive moat. However, the high valuation and dependence on a single product warrant a medium confidence level. If the company can sustain growth and expand its pipeline, the stock has significant upside. Key developments to watch include quarterly earnings, pipeline data, and competitive landscape changes. A downgrade to neutral would occur if revenue growth decelerates below 20% or if a major pipeline failure occurs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Krystal Biotech, Inc.'s 12-month outlook, with a consensus price target around $384.43 and implied upside of +23.0% versus the current price.
Average Target
$384.43
0 analysts
Implied Upside
+23.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$284 - $474
Analyst target range
The wide spread between the low and high targets ($284 to $474) indicates high uncertainty about the company's future, reflecting the binary nature of biotech pipeline success and the potential for competitive threats. The low target of $284 implies a downside of -16.7% from the current price, suggesting that even the most bearish analyst sees value in the stock, but it also highlights the risk of a pullback if growth disappoints. The high target of $474 assumes successful expansion of VYJUVEK into new indications and geographies, as well as potential multiple expansion as the company proves its platform's scalability. With no recent downgrades and a strong buy consensus, the analyst community remains confident in Krystal Biotech's growth story, but the wide target range underscores the speculative nature of the stock.
Bulls vs Bears: KRYS Investment Factors
Krystal Biotech presents a compelling bull case with accelerating revenue growth, exceptional margins, and strong profitability, supported by a robust balance sheet and a unique platform. However, the stock's high valuation multiples and dependence on a single product introduce significant risk. Currently, the bull case has stronger evidence given the consistent financial performance and analyst confidence, but the key tension is whether the company can sustain its growth trajectory and expand its pipeline to justify the premium valuation. If VYJUVEK continues to grow and pipeline advances, the stock could re-rate higher; if growth decelerates or competition emerges, the stock could face a sharp correction.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue of $116.36 million grew 31.95% YoY, up from $88.18 million in Q1 2025, with sequential growth from $107.11 million in Q4 2025. This marks the eighth consecutive quarter of revenue increases, demonstrating strong commercial execution of VYJUVEK.
- High Gross Margins: Gross margin for Q1 2026 was 94.57%, up from 94.30% in Q1 2025, reflecting the scalable nature of gene therapy manufacturing. This exceptional margin profile supports strong profitability and cash flow generation.
- Strong Profitability: Q1 2026 net income was $55.93 million with a net margin of 48.07%, and operating margin was 46.14%. The company is consistently profitable, with trailing twelve-month free cash flow of $237.38 million.
- Undervalued on PEG: With a PEG ratio of 0.27, the stock is trading at a significant discount to its expected earnings growth. This suggests the market is not fully pricing in the company's growth potential, offering upside if growth continues.
Bearish
- High Valuation Multiples: The stock trades at a trailing PE of 34.82x and a forward PE of 34.56x, which is elevated compared to the broader market. The PS ratio of 18.34x and EV/Sales of 23.96x are extremely high, leaving little room for error.
- Recent Price Volatility: The stock has pulled back 7.01% in the last trading day and is down 8.20% over the past month, despite a strong 1-year gain of 121.69%. This volatility suggests profit-taking and uncertainty about near-term catalysts.
- Dependence on Single Product: VYJUVEK is the only approved product, and revenue is heavily concentrated in this one drug. Any setback in manufacturing, reimbursement, or competition could significantly impact the company's financials.
- Wide Analyst Target Range: The analyst low target of $284 implies a downside of -16.7% from the current price, while the high target of $474 suggests 38.9% upside. This wide spread indicates high uncertainty about the company's future, typical of biotech stocks.
KRYS Technical Analysis
The stock is in a strong long-term uptrend, with a 1-year price change of +121.69%, significantly outperforming the S&P 500's +18.19% over the same period. Currently trading at $341.12, the stock is positioned at 84.6% of its 52-week range (between $130.50 low and $382.535 high), indicating it remains near the highs despite a recent pullback. This positioning suggests robust momentum but also potential overextension, as the stock has more than doubled from its 52-week low. The 6-month price change of +22.16% and YTD change of +38.16% reinforce the bullish trend, though the recent decline from the high warrants attention.
Beta
0.54
0.54x market volatility
Max Drawdown
-17.3%
Largest decline past year
52-Week Range
$131-$383
Price range past year
Annual Return
+99.1%
Cumulative gain past year
| Period | KRYS Return | S&P 500 |
|---|---|---|
| 1m | -16.7% | +1.7% |
| 3m | +9.8% | +4.7% |
| 6m | +16.1% | +10.4% |
| 1y | +99.1% | +21.9% |
| ytd | +26.6% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KRYS Fundamental Analysis
Krystal Biotech's revenue trajectory is strongly accelerating, with Q1 2026 revenue of $116.36 million, up 31.95% year-over-year, and sequential growth from $107.11 million in Q4 2025 and $97.80 million in Q3 2025. The company has demonstrated consistent quarterly revenue increases over the past eight quarters, from $70.28 million in Q2 2024 to the current level, reflecting robust commercial execution of VYJUVEK. This growth is driven by strong patient demand and geographic expansion, with the company now marketing in the EU and Japan, which should sustain momentum. The accelerating growth trajectory supports the investment case for a company transitioning from a niche rare disease player to a broader genetic medicine platform.
Quarterly Revenue
$116357000.0B
2026-03
Revenue YoY Growth
+31.9%
YoY Comparison
Gross Margin
94.6%
Latest Quarter
Free Cash Flow
$237383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KRYS Overvalued?
Given that Krystal Biotech is profitable with a trailing EPS of $0.0287 (though this is distorted by one-time items; the quarterly EPS is $1.91), the PE ratio is the most appropriate valuation metric. The trailing PE is 34.82x, while the forward PE is 34.56x, indicating that the market expects earnings to remain stable in the near term. The PE gap is minimal, suggesting that the market's growth expectations are already priced in, with a PEG ratio of 0.27 implying that the stock is undervalued relative to its expected earnings growth. However, the PE ratio is based on the last twelve months' earnings, which include significant tax benefits and one-time items, so investors should focus on the forward PE and the company's ability to sustain profitability.
PE
34.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~100x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include the company's high valuation, which leaves little room for disappointment. With a trailing PE of 34.82x and a PS ratio of 18.34x, any miss in revenue or earnings could trigger a significant de-rating. The company's profitability is partly driven by tax benefits and one-time items, as seen in Q3 2025's net income of $79.37 million on revenue of $97.80 million, which included a $31.40 million tax benefit. Excluding such items, the underlying earnings power may be lower, making the forward PE less reliable. Additionally, the company's cash flow generation, while positive, is still modest relative to its market cap, and any increase in R&D spending for pipeline expansion could pressure margins.
FAQ
The key risks include: 1) High valuation multiples (PE 34.82x, PS 18.34x) leaving little room for error; 2) Dependence on VYJUVEK as the sole revenue source, making the company vulnerable to competition or regulatory issues; 3) Pipeline risk, as future growth depends on successful development of new indications; 4) Market volatility, with the stock down 8.20% in the past month despite a strong 1-year gain. The most severe risk is a significant slowdown in revenue growth, which could lead to a de-rating and a potential decline to the 52-week low of $130.50.
The 12-month forecast for KRYS is positive, with a base case target of $376.75 (10.4% upside) and a bull case target of $474 (38.9% upside). The bear case target is $284 (-16.7% downside). The base case assumes continued revenue growth of 25-30% and stable margins, with a 50% probability. The bull case, with a 30% probability, assumes faster growth and pipeline success. The bear case, with a 20% probability, assumes growth deceleration and competitive pressures. Overall, the most likely scenario is a gradual appreciation toward the average target, driven by strong fundamentals.
KRYS is trading at a trailing PE of 34.82x and a forward PE of 34.56x, which is higher than the broader market but reasonable for a high-growth biotech. The PEG ratio of 0.27 suggests the stock is undervalued relative to its expected earnings growth, implying the market is not fully pricing in future growth. However, the PS ratio of 18.34x is extremely high, indicating that revenue growth must continue to justify the valuation. Overall, the stock appears fairly valued to slightly undervalued based on growth prospects, but investors should be cautious about the high multiples.
KRYS is a good buy for investors with a high risk tolerance and a long-term horizon. The stock offers strong growth potential, with Q1 2026 revenue up 31.95% YoY and a PEG ratio of 0.27, indicating undervaluation relative to growth. However, the high valuation (PE of 34.82x) and dependence on a single product introduce significant risk. The average analyst target of $376.75 implies 10.4% upside, but the low target of $284 suggests potential downside of -16.7%. Investors should consider their risk appetite and portfolio diversification before buying.
KRYS is more suitable for long-term investment due to its growth stage and volatility. The stock has a beta of 0.497, which is lower than the market, but its 1-year price change of +121.69% and recent pullback indicate significant short-term volatility. The company is profitable and has a strong balance sheet, but its valuation is high, and pipeline developments will take time to materialize. A minimum holding period of 3-5 years is recommended to allow the company to expand its product portfolio and realize the full potential of its platform. Short-term traders may find opportunities, but the risk is elevated.